Fas ligand (FasL) has been reported to be highly expressed in various types of tumor cell-derived exosomes, including ovarian cancer [56], melanoma [54], prostate cancer [57], and oral squamous cell carcinoma [58]. Here, FASLG is linked to ovarian carcinoma.